241 related articles for article (PubMed ID: 30796356)
1. mTORC1 inhibitor RAD001 (everolimus) enhances non-small cell lung cancer cell radiosensitivity in vitro via suppressing epithelial-mesenchymal transition.
Chen Y; Li WW; Peng P; Zhao WH; Tian YJ; Huang Y; Xia S; Chen Y
Acta Pharmacol Sin; 2019 Aug; 40(8):1085-1094. PubMed ID: 30796356
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Combined Use of Everolimus and Second-Generation Pan-EGRF Inhibitors in
da Silva-Oliveira RJ; Gomes INF; da Silva LS; Lengert AVH; Laus AC; Melendez ME; Munari CC; Cury FP; Longato GB; Reis RM
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887120
[TBL] [Abstract][Full Text] [Related]
3. Combined inhibition of the EGFR and mTOR pathways in EGFR wild-type non-small cell lung cancer cell lines with different genetic backgrounds.
Huang Y; Chen Y; Mei Q; Chen Y; Yu S; Xia S
Oncol Rep; 2013 Jun; 29(6):2486-92. PubMed ID: 23525575
[TBL] [Abstract][Full Text] [Related]
4. A Novel mTORC1/2 Inhibitor (MTI-31) Inhibits Tumor Growth, Epithelial-Mesenchymal Transition, Metastases, and Improves Antitumor Immunity in Preclinical Models of Lung Cancer.
Zhang Q; Zhang Y; Chen Y; Qian J; Zhang X; Yu K
Clin Cancer Res; 2019 Jun; 25(12):3630-3642. PubMed ID: 30796032
[TBL] [Abstract][Full Text] [Related]
5. LKB1 gene inactivation does not sensitize non-small cell lung cancer cells to mTOR inhibitors in vitro.
Xiao P; Sun LL; Wang J; Han RL; Ma Q; Zhong DS
Acta Pharmacol Sin; 2015 Sep; 36(9):1107-12. PubMed ID: 26027660
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of mTORC1 induces loss of E-cadherin through AKT/GSK-3β signaling-mediated upregulation of E-cadherin repressor complexes in non-small cell lung cancer cells.
Kim EY; Kim A; Kim SK; Kim HJ; Chang J; Ahn CM; Chang YS
Respir Res; 2014 Feb; 15(1):26. PubMed ID: 24571487
[TBL] [Abstract][Full Text] [Related]
7. Triptolide suppresses the growth and metastasis of non-small cell lung cancer by inhibiting β-catenin-mediated epithelial-mesenchymal transition.
Deng QD; Lei XP; Zhong YH; Chen MS; Ke YY; Li Z; Chen J; Huang LJ; Zhang Y; Liang L; Lin ZX; Liu Q; Li SP; Yu XY
Acta Pharmacol Sin; 2021 Sep; 42(9):1486-1497. PubMed ID: 33893396
[TBL] [Abstract][Full Text] [Related]
8. Rhamnetin and cirsiliol induce radiosensitization and inhibition of epithelial-mesenchymal transition (EMT) by miR-34a-mediated suppression of Notch-1 expression in non-small cell lung cancer cell lines.
Kang J; Kim E; Kim W; Seong KM; Youn H; Kim JW; Kim J; Youn B
J Biol Chem; 2013 Sep; 288(38):27343-27357. PubMed ID: 23902763
[TBL] [Abstract][Full Text] [Related]
9. Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer.
Ferrarotto R; Goonatilake R; Yoo SY; Tong P; Giri U; Peng S; Minna J; Girard L; Wang Y; Wang L; Li L; Diao L; Peng DH; Gibbons DL; Glisson BS; Heymach JV; Wang J; Byers LA; Johnson FM
Clin Cancer Res; 2016 Apr; 22(7):1674-1686. PubMed ID: 26597303
[TBL] [Abstract][Full Text] [Related]
10. Reduction of metastatic potential by inhibiting EGFR/Akt/p38/ERK signaling pathway and epithelial-mesenchymal transition after carbon ion exposure is potentiated by PARP-1 inhibition in non-small-cell lung cancer.
Chowdhury P; Dey P; Ghosh S; Sarma A; Ghosh U
BMC Cancer; 2019 Aug; 19(1):829. PubMed ID: 31438892
[TBL] [Abstract][Full Text] [Related]
11. Implication of epithelial-mesenchymal transition in IGF1R-induced resistance to EGFR-TKIs in advanced non-small cell lung cancer.
Zhou J; Wang J; Zeng Y; Zhang X; Hu Q; Zheng J; Chen B; Xie B; Zhang WM
Oncotarget; 2015 Dec; 6(42):44332-45. PubMed ID: 26554308
[TBL] [Abstract][Full Text] [Related]
12. Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C-Mutant Non-Small Cell Lung Cancer.
Adachi Y; Ito K; Hayashi Y; Kimura R; Tan TZ; Yamaguchi R; Ebi H
Clin Cancer Res; 2020 Nov; 26(22):5962-5973. PubMed ID: 32900796
[TBL] [Abstract][Full Text] [Related]
13. Potentiation of the anticancer effects of everolimus using a dual mTORC1/2 inhibitor in hepatocellular carcinoma cells.
Kim JO; Kim KH; Song IS; Cheon KS; Kim OH; Lee SC; Lee SK; Kim SJ
Oncotarget; 2017 Jan; 8(2):2936-2948. PubMed ID: 27935857
[TBL] [Abstract][Full Text] [Related]
14. Synergistic anticancer effects of everolimus (RAD001) and Rhein on gastric cancer cells via phosphoinositide-3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway.
Gao F; Li R; Wei PF; Ou L; Li M; Bai Y; Luo WJ; Fan Z
Bioengineered; 2022 Mar; 13(3):6332-6342. PubMed ID: 35209807
[TBL] [Abstract][Full Text] [Related]
15. Protein Tyrosine Phosphatase Non-Receptor 11 (
Richards CE; Elamin YY; Carr A; Gately K; Rafee S; Cremona M; Hanrahan E; Smyth R; Ryan D; Morgan RK; Kennedy S; Hudson L; Fay J; O'Byrne K; Hennessy BT; Toomey S
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445722
[No Abstract] [Full Text] [Related]
16. Everolimus (RAD001) combined with programmed death-1 (PD-1) blockade enhances radiosensitivity of cervical cancer and programmed death-ligand 1 (PD-L1) expression by blocking the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR)/S6 kinase 1 (S6K1) pathway.
Song L; Liu S; Zhao S
Bioengineered; 2022 Apr; 13(4):11240-11257. PubMed ID: 35485300
[TBL] [Abstract][Full Text] [Related]
17. β-Elemene enhances radiosensitivity in non-small-cell lung cancer by inhibiting epithelial-mesenchymal transition and cancer stem cell traits via Prx-1/NF-kB/iNOS signaling pathway.
Zou K; Li Z; Zhang Y; Mu L; Chen M; Wang R; Deng W; Zou L; Liu J
Aging (Albany NY); 2020 Dec; 13(2):2575-2592. PubMed ID: 33316778
[TBL] [Abstract][Full Text] [Related]
18. ITGB1 enhances the Radioresistance of human Non-small Cell Lung Cancer Cells by modulating the DNA damage response and YAP1-induced Epithelial-mesenchymal Transition.
Li Y; Sun C; Tan Y; Zhang H; Li Y; Zou H
Int J Biol Sci; 2021; 17(2):635-650. PubMed ID: 33613118
[No Abstract] [Full Text] [Related]
19. Inactivation of M2 AChR/NF-κB signaling axis reverses epithelial-mesenchymal transition (EMT) and suppresses migration and invasion in non-small cell lung cancer (NSCLC).
Zhao Q; Yue J; Zhang C; Gu X; Chen H; Xu L
Oncotarget; 2015 Oct; 6(30):29335-46. PubMed ID: 26336823
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of Human Papillomavirus Type 16 Oncoproteins Enhances Epithelial-Mesenchymal Transition via STAT3 Signaling Pathway in Non-Small Cell Lung Cancer Cells.
Zhang W; Wu X; Hu L; Ma Y; Xiu Z; Huang B; Feng Y; Tang X
Oncol Res; 2017 May; 25(5):843-852. PubMed ID: 28508744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]